Wedge Capital Management L L P NC boosted its position in Amgen, Inc. (NASDAQ:AMGN) by 17.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 259,044 shares of the medical research company’s stock after purchasing an additional 38,005 shares during the quarter. Wedge Capital Management L L P NC’s holdings in Amgen were worth $45,048,000 at the end of the most recent quarter.
A number of other large investors have also recently modified their holdings of AMGN. Sfmg LLC increased its stake in Amgen by 0.5% during the 2nd quarter. Sfmg LLC now owns 8,564 shares of the medical research company’s stock valued at $1,475,000 after buying an additional 39 shares during the period. Boys Arnold & Co. Inc. grew its stake in shares of Amgen by 4.1% in the 2nd quarter. Boys Arnold & Co. Inc. now owns 6,293 shares of the medical research company’s stock worth $1,084,000 after purchasing an additional 250 shares during the last quarter. Willingdon Wealth Management grew its stake in shares of Amgen by 3.2% in the 2nd quarter. Willingdon Wealth Management now owns 6,779 shares of the medical research company’s stock worth $1,168,000 after purchasing an additional 210 shares during the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund grew its stake in shares of Amgen by 14.0% in the 2nd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 169,993 shares of the medical research company’s stock worth $29,278,000 after purchasing an additional 20,885 shares during the last quarter. Finally, BDO Wealth Advisors LLC acquired a new position in shares of Amgen in the 2nd quarter worth approximately $145,000. Hedge funds and other institutional investors own 79.61% of the company’s stock.
Shares of Amgen, Inc. (AMGN) opened at $189.00 on Monday. The company has a current ratio of 5.49, a quick ratio of 5.17 and a debt-to-equity ratio of 1.35. The company has a market cap of $137,700.00, a P/E ratio of 17.37, a P/E/G ratio of 2.35 and a beta of 1.37. Amgen, Inc. has a fifty-two week low of $152.16 and a fifty-two week high of $201.23.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Shareholders of record on Thursday, May 17th will be paid a $1.32 dividend. This represents a $5.28 dividend on an annualized basis and a yield of 2.79%. The ex-dividend date of this dividend is Wednesday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 48.00%.
Amgen announced that its board has initiated a share buyback plan on Thursday, February 1st that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the medical research company to purchase shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.
Several brokerages have recently issued reports on AMGN. Leerink Swann reaffirmed a “market perform” rating on shares of Amgen in a research note on Friday, February 2nd. Atlantic Securities cut shares of Amgen from an “overweight” rating to a “neutral” rating and set a $187.01 price objective on the stock. in a research note on Monday, February 5th. BidaskClub raised shares of Amgen from a “sell” rating to a “hold” rating in a research note on Thursday, January 18th. Oppenheimer set a $205.00 price objective on shares of Amgen and gave the stock a “buy” rating in a research note on Friday, January 5th. Finally, Credit Suisse Group lifted their price objective on shares of Amgen from $191.00 to $194.00 and gave the stock a “neutral” rating in a research note on Friday, February 2nd. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $191.72.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction that occurred on Wednesday, February 14th. The shares were sold at an average price of $174.18, for a total value of $265,624.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 4,575 shares of company stock valued at $818,361 over the last quarter. Corporate insiders own 0.19% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/03/12/wedge-capital-management-l-l-p-nc-purchases-38005-shares-of-amgen-inc-amgn.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.